Clinical Trials
15 trialsNCT05267106 2025-12-30
FIGHT-209
Incyte Corporation
Phase 2 Terminated
NCT05297864 2025-05-23
OU-SCC-PI-4G
University of Oklahoma
Phase 2 Terminated
NCT02372409 2024-11-01
Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors
Washington University School of Medicine
Phase 2 Terminated
NCT01986348 2023-01-26
KING
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT02023905 2022-12-29
Everolimus With and Without Temozolomide in Adult Low Grade Glioma
University of California, San Francisco
Phase 2 Terminated
NCT01478321 2020-03-12
Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
Northwestern University
Phase 2 Terminated
NCT01966809 2019-08-20
Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas
Medical College of Wisconsin
Phase 2 Terminated
NCT00243022 2019-04-30
Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT01836549 2018-07-20
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Pediatric Brain Tumor Consortium
Phase 2 Terminated
NCT00003472 2018-03-21
Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma
Burzynski Research Institute
Phase 2 Terminated
NCT00360828 2017-03-23
Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01095094 2013-06-10
Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT00389090 2012-02-09
A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma
Keryx / AOI Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00062504 2011-05-23
Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Terminated
NCT00848523 2010-07-16
Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors
Neurological Surgery, P.C.
Phase 2 Terminated